Invea Therapeutics

Private

Guilford, ConnecticutHealthcare & Life Scienceshttps://inveatx.com/

Last Round

IPO Announced

Mar 6, 2026

Est. Valuation

$127.5M

Total Funding Raised

$14.76M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Invea Therapeutics is a biotechnology company developing oral small molecule therapeutics for immune-mediated inflammatory diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoveryAI drug discoverysmall-molecule therapyimmune-mediated inflammatory diseasesIMIDchymase inhibitorAI-driven biotechclinical-stage biotechinflammasome inhibitorin silico drug discoverymast cell inflammationtherapeutic out-licensingpharma R&DAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Invea Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Invea Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Invea Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
IPO Announced	Mar 6, 2026
Convertible Debt	Mar 31, 2025
SAFE	Mar 22, 2023
Series A Extension	Feb 22, 2023
Series A	Apr 22, 2022
Debt	Nov 24, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Aman Kant

Co-founder And Chief Operating Officer

Founding Team

Krishnan Nandabalan

Founder, Chairman, President, CEO

Founding Team

Michael Aiello

Chief Financial Officer

Executive Team

Michael J. Aiello

Chief Financial Officer

Executive Team

View all key people

Invea Therapeutics Investors

Notable investors and investment history

Invea Therapeutics investors
Investor	Rounds
Connecticut Innovations	Series A, Series A Extension
ThinkEquity	IPO

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 19, 2026
Monthly visitors grew 1200% MoM, from 1.2K to 16K.

View all signals

Invea Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Invea Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Invea Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersGuilford, Connecticut

Employee Range11

Year Founded2021

Last FundingMar 6, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.